Tag: PFS and overall survival (OS)
-
Clarify the real-world efficacy and safety of second-line Toripalimab, we assessed 95 consecutive patients with advanced nonesmall-cell lung cancer in a retrospective multi center trial.
Real-World Efficacy of Second-Line Toripalimab in Patients With Advanced None Small-Cell Lung Cancer To clarify the real-world efficacy and safety of second-line Toripalimab, we assessed 95 consecutive patients with advanced nonesmall-cell lung cancer in a retrospective multi center trial. Non adenocarcinoma and a large number of metastatic sites correlated with poor progression-free sur vival (PFS).…